Table 2.
Hazard ratios (HR) with 95% confidence interval (CI) for menstruation disorders after each dose in one to seven days and 8-90 days risk windows, among women in a Swedish population cohort
| Risk windows | Person-years | Cases | Incidence rate (per 100 000 person-years) |
Crude model,* HR (95% CI) | Full model,†
HR (95% CI) |
|---|---|---|---|---|---|
| Postmenopausal bleeding (45-74 years, n=1 561 429) | |||||
| Unvaccinated | 646 133 | 3144 | 486.6 | ref | ref |
| Any dose: | |||||
| 1-7 days | 77 501 | 416 | 536.8 | 1.19 (1.06 to 1.33) | 1.12 (1.00 to 1.25) |
| 8-90 days | 665 572 | 3401 | 511.0 | 1.21 (1.13 to 1.29) | 1.14 (1.06 to 1.23) |
| Dose 1: | |||||
| 1-7 days | 27 379 | 166 | 606.3 | 1.20 (1.02 to 1.41) | 1.15 (0.98 to 1.35) |
| 8-90 days | 159 069 | 844 | 530.6 | 1.14 (1.04 to 1.25) | 1.08 (0.98 to 1.19) |
| Dose 2: | |||||
| 1-7 days | 27 216 | 122 | 448.3 | 1.06 (0.88 to 1.29) | 0.98 (0.81 to 1.19) |
| 8-90 days | 320 329 | 1561 | 487.3 | 1.22 (1.11 to 1.34) | 1.14 (1.03 to 1.25) |
| Dose 3: | |||||
| 1-7 days | 22 907 | 128 | 558.8 | 1.45 (1.14 to 1.84) | 1.28 (1.01 to 1.62) |
| 8-90 days | 186 174 | 996 | 535.0 | 1.40 (1.17 to 1.67) | 1.25 (1.04 to 1.50) |
| Menstrual disturbance (12-49 years, n=1 634 294) | |||||
| Unvaccinated | 1 067 762 | 9615 | 900.5 | ref | ref |
| Any dose: | |||||
| 1-7 days | 62 278 | 674 | 1082.2 | 1.41 (1.29 to 1.52) | 1.13 (1.04 to 1.23) |
| 8-90 days | 480 493 | 4970 | 1034.4 | 1.38 (1.32 to 1.44) | 1.06 (1.01 to 1.11) |
| Dose 1: | |||||
| 1-7 days | 26 034 | 288 | 1106.2 | 1.49 (1.32 to 1.68) | 1.26 (1.11 to 1.42) |
| 8-90 days | 147 296 | 1364 | 926.0 | 1.29 (1.21 to 1.37) | 1.07 (1.00 to 1.14) |
| Dose 2: | |||||
| 1-7 days | 24 969 | 250 | 1001.2 | 1.21 (1.06 to 1.37) | 1.04 (0.91 to 1.18) |
| 8-90 days | 281 999 | 2981 | 1057.1 | 1.33 (1.26 to 1.40) | 1.04 (0.98 to 1.10) |
| Dose 3: | |||||
| 1-7 days | 11 274 | 136 | 1206.3 | 1.34 (1.11 to 1.62) | 1.02 (0.84 to 1.23) |
| 8-90 days | 51 198 | 625 | 1220.8 | 1.43 (1.27 to 1.62) | 1.00 (0.89 to 1.13) |
| Premenopausal bleeding (12-49 years, n=1 634 294) | |||||
| Unvaccinated | 1 070 500 | 1865 | 174.2 | ref | ref |
| Any dose: | |||||
| 1-7 days | 62 625 | 133 | 212.4 | 1.44 (1.2 to 1.74) | 1.08 (0.90 to 1.30) |
| 8-90 days | 484 600 | 1002 | 206.8 | 1.43 (1.3 to 1.58) | 1.01 (0.91 to 1.12) |
| Dose 1: | |||||
| 1-7 days | 26 144 | 54 | 206.6 | 1.40 (1.06 to 1.85) | 1.14 (0.86 to 1.50) |
| 8-90 days | 148 118 | 273 | 184.3 | 1.32 (1.14 to 1.51) | 1.01 (0.88 to 1.16) |
| Dose 2: | |||||
| 1-7 days | 25 096 | 46 | 183.3 | 1.22 (0.90 to 1.65) | 0.96 (0.71 to 1.30) |
| 8-90 days | 284 736 | 608 | 213.5 | 1.45 (1.29 to 1.63) | 1.03 (0.92 to 1.17) |
| Dose 3: | |||||
| 1-7 days | 11 385 | 33 | 289.9 | 1.67 (1.13 to 2.49) | 1.14 (0.77 to 1.70) |
| 8-90 days | 51 745 | 121 | 233.8 | 1.32 (1.00 to 1.75) | 0.83 (0.63 to 1.10) |
*
Crude model included no covariates.
†
Full model included age, country of birth, employed as a healthcare worker, marital status, education, and health seeking behaviours during 2018-19 (ie, no. of primary care visits, number of specialist outpatient visits, and days of inpatient stay), and prior comorbidities and treatments listed in supplement table S1.